Pfizer's Lyrica fails to best placebo in back pain; Novartis plots 22 more layoffs in NY; Lundbeck touts new Brintellix data;

@FiercePharma: Germany bans dozens of drugs made by Dr. Reddy's, Unichem, others because of issues at GVK Bio. Story | Follow @FiercePharma

@CarlyHFierce: New financing helps Anergis take allergy vaccine to Phase III. More | Follow @CarlyHFierce

> Pfizer's ($PFE) pain drug Lyrica, its top-selling product, failed a trial in patients with back pain, offering no more improvement than placebo. Report

> Novartis ($NVS) filed official plans for its third phase of layoffs in Suffern, NY; 22 employees will lose their jobs in early April. Report

> Lundbeck rolled out new data on its antidepressant Brintellix, its next-gen drug intended to replace sales lost to Cipralex generics; the study showed that Brintellix improved patients' memory performance. Report

> Alexion Pharmaceuticals says its rare disease treatment Soliris won orphan drug designation in Japan for treatment of patients with myasthenia gravis. Release

> European officials say fewer branded drugmakers struck patent settlements with generics companies in 2013, with 146 deals in Europe that year, compared with 183 in 2012. Report

> Cardiovascular medtech company HeartFlow has tapped former Johnson & Johnson ($JNJ) CEO William Weldon to serve on its board. Release

> Agios Pharmaceutiucals says it set a 1.98 million share stock offering at a price of $110.75 per share, expecting proceeds to hit $220 million. Release

Medical Device News

@FierceMedDev: Startup gains FDA clearance for breast surgery guidance system. Story | Follow @FierceMedDev

@EmilyWFierce: C.R. Bard battling bid from plaintiffs to consolidate pelvic mesh suits. More | Follow @EmilyWFierce

> St. Jude gains CE mark for first pacemaker with MultiPoint Pacing. Article

> Omron partnership to give AliveCor more retail punch. News

Biotech News

@FierceBiotech: Amicus eyes a 2015 EU filing for its rare disease drug with FDA in sight. Article | Follow @FierceBiotech

@DamianFierce: The @nytimes digs into the medicinal ketamine issue, with cameos from Naurex, Cerecor and $JNJ. More | Follow @DamianFierce

> Naurex posts the positive PhIIb data that helped it reel in $80M. Story

> Merck hits a hiccup with its new Ebola vaccine. News

> Bellicum battles for CAR-T spotlight with a $121M IPO pitch. Article

Vaccines News

> Amgen tests T-Vec's combo potential in trial with Merck's Keytruda. More

> Merck Vaccines president Gerberding leaving post for EVP role. Item

> Ebola vaccine makers Merck, GSK, J&J get legal protections in U.S. thanks to HHS declaration. Report

> Merck wins FDA approval for Gardasil follow-up. Story

> PaxVax meets primary endpoints in PhIII cholera vaccine trial. Article

Pharma Manufacturing News

> AstraZeneca closing U.S. plant, costing 180 jobs. Story

> More Novartis jobs cut in New York as plant suffers drawn-out drawdown. Report

> Romark building $110M plant in Puerto Rico. More

> Indonesia's Indofarma and Kimia combine manufacturing, supply chain strengths. News

> Indian drugmakers lambast proposed PET packaging ban. Article

And Finally... Drug-resistant superbugs could cost the global economy as much as $100 trillion by 2050, according to a review by a Goldman Sachs economist in the U.K. Report

Suggested Articles

Former Indivior CEO Shaun Thaxter will face six months in federal prison for his role in misleading government officials on the dangers of Suboxone.

As of Friday after local time, 36 people have died in Korea after getting flu shots provided by at least seven companies, including Sanofi.

Two prominent pneumococcal vaccines from Merck and Pfizer are running low in Europe in a possible ill omen for the coming winter: report.